** Shares in Denmark's Novo Nordisk NOVOb.CO rise around 3% after it dropped its bid for obesity drug developer Metsera MTSR.O
** Metsera accepted the offer from Pfizer PFE.N late on Friday, while Novo said on Saturday it would not be making an increased offer and said it would exit the race
** "Metsera is out of sight for investors, and it sounds more negative than it probably is," Nordnet analyst Per Hansen says
(Reporting by Elviira Luoma)
((Elviira.luoma@thosmonreuters.com))